References
- Law L, Beckman Rehnman J, Deminger A, Klingberg E, Jacobsson LTH, Forsblad-d’Elia H. Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex. Arthritis Res Ther. 2018;20(1):284. doi:10.1186/s13075-018-1784-8
- Lories RJ, Haroon N. Evolving concepts of new bone formation in axial spondyloarthritis: insights from animal models and human studies. Best Pract Res Clin Rheumatol. 2017;31(6):877–886. doi:10.1016/j.berh.2018.07.007
- Lu MC, Huang KY, Tung CH, et al. Factors associated with disease-specific quality of life in Taiwanese patients with ankylosing spondylitis: a cross-sectional study. BMJ Open. 2019;9(6):e028966. doi:10.1136/bmjopen-2019-028966
- Rheumatology Society of Chinese Medical Association. Guidelines for diagnosis and treatment of ankylosing spondylitis. Chin J Rheumatol. 2010;14(8):557–559.
- Wakai M, Hayashi R, Tanaka S, et al. Serum amyloid A is a better predictive biomarker of mucosal healing than C-reactive protein in ulcerative colitis in clinical remission. BMC Gastroenterol. 2020;20(1):85. doi:10.1186/s12876-020-01229-8
- Zhou H, Chen M, Zhang G, Ye RD. Suppression of lipopolysaccharide-induced inflammatory response by fragments from serum amyloid A. J Immunol. 2017;199(3):1105–1112. doi:10.4049/jimmunol.1700470
- Facci L, Barbierato M, Zusso M, Skaper SD, Giusti P. Serum amyloid A primes microglia for ATP-dependent interleukin-1β release. J Neuroinflammation. 2018;15(1):164. doi:10.1186/s12974-018-1205-6
- Jamalyaria F, Ward MM, Assassi S, et al. Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups. Clin Rheumatol. 2017;36(10):2359–2364. doi:10.1007/s10067-017-3767-6
- Hong C, Kwan YH, Leung YY, Lui NL, Fong W. Comparison of ankylosing spondylitis and non-radiographic axial spondyloarthritis in a multi-ethnic Asian population of Singapore. Int J Rheum Dis. 2019;22(8):1506–1511. doi:10.1111/1756-185X.13603
- Jones GT, Mallawaarachchi B, Shim J, Lock J, Macfarlane GJ. The prevalence of fibromyalgia in axial spondyloarthritis. Rheumatol Int. 2020;40(10):1581–1591. doi:10.1007/s00296-020-04621-5
- Laboratory Medicine Committee of Chinese Association of Integrated Traditional and Western Medicine. The clinical application of serum amyloid A in infectious diseases. Chin J Lab Med. 2019;42(3):186–192.
- Li FY, Lv Z. Clinical significance of serum SAA and MMP-3 levels in patients with ankylosing spondylitis. Clin Res. 2018;26(6):44–45.
- de Vries MK, van Eijk IC, van der Horst‐bruinsma IE, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum. 2009;61(11):1484–1490. doi:10.1002/art.24838
- Jung SY, Park MC, Park YB, Lee SK. Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J. 2007;48(2):218–224. doi:10.3349/ymj.2007.48.2.218
- Fellahi S, Béraud L, Capeau J, et al. Validation des valeurs usuelles proposées par un fournisseur sans accès à une population témoin: exemple de la sérum amyloïde A [Validation of the usual values provided by a supplier without access to a control population: example of serum amyloid A]. Ann Biol Clin (Paris). 2019;77(3):255–259. doi:10.1684/abc.2019.1439
- Li DX, Xu SQ, Wu Y, et al. Comparison of BASDAI and ASDAScrp in a measure of disease activity in patients with spondyloarthropathy. Gen Pract Res. 2017;15(1):11–12.